The rollout of 2 novel malaria vaccines (RTS,S and R21) in sub-Saharan Africa in 2024for children in medium and high-transmission areas marks the success of decades ofmalaria vaccine research [1].These circumsporozoite protein (CSP)-based vaccines now provide the much-neededadditional tool to control the increasing number of malaria cases. The gene discussed is DNAJC5; the disease is malaria.